Literature DB >> 2812318

Regional cerebral glucose transport and utilization in Alzheimer's disease.

R P Friedland1, W J Jagust, R H Huesman, E Koss, B Knittel, C A Mathis, B A Ober, B M Mazoyer, T F Budinger.   

Abstract

We performed dynamic positron emission tomographic (PET) studies of glucose utilization, using (18F) 2-fluoro-2-deoxy-D-glucose (FDG), in patients with probable Alzheimer's disease (AD) and healthy age-matched controls, to evaluate blood-brain-barrier glucose transport and glucose utilization rates in the disease. We found no significant differences in rate constants for glucose transport (k1 and k2) and phosphorylation (k3), nor for the vascular fraction (fv), between the 2 groups, although k3 and fv were relatively depressed in temporal cortex in AD. Absolute rates of glucose use were depressed in temporal and parietal cortex, and relative rCMRglc rates were lower in frontal, temporal, parietal, and occipital cortices. These data suggest that in AD bidirectional glucose transport is intact, and that temporal-parietal hypometabolism is present upon a background of widespread cortical metabolic impairment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2812318     DOI: 10.1212/wnl.39.11.1427

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

Review 1.  A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer's type: a neuroimaging profile.

Authors:  Konstantine K Zakzanis; Simon J Graham; Zachariah Campbell
Journal:  Neuropsychol Rev       Date:  2003-03       Impact factor: 7.444

Review 2.  Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.

Authors:  Simon G Patching
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

3.  Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease.

Authors:  Lisa Mosconi; Wai H Tsui; Henry Rusinek; Susan De Santi; Yi Li; Gene-Jack Wang; Alberto Pupi; Joanna Fowler; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-04       Impact factor: 9.236

Review 4.  The facilitative glucose transporter GLUT3: 20 years of distinction.

Authors:  Ian A Simpson; Donard Dwyer; Daniela Malide; Kelle H Moley; Alexander Travis; Susan J Vannucci
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-24       Impact factor: 4.310

5.  Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors.

Authors:  Kyle B Womack; Ramon Diaz-Arrastia; Howard J Aizenstein; Steven E Arnold; Nancy R Barbas; Bradley F Boeve; Christopher M Clark; Charles S DeCarli; William J Jagust; James B Leverenz; Elaine R Peskind; R Scott Turner; Edward Y Zamrini; Judith L Heidebrink; James R Burke; Steven T DeKosky; Martin R Farlow; Matthew J Gabel; Roger Higdon; Claudia H Kawas; Robert A Koeppe; Anne M Lipton; Norman L Foster
Journal:  Arch Neurol       Date:  2010-11-08

Review 6.  Neuroanatomical Differences Among Sexual Offenders: A Targeted Review with Limitations and Implications for Future Directions.

Authors:  Katelyn T Kirk-Provencher; Rebecca J Nelson-Aguiar; Nichea S Spillane
Journal:  Violence Gend       Date:  2020-09-11

7.  Immunolabelling of hippocampal microvessel glucose transporter protein is reduced in Alzheimer's disease.

Authors:  N Horwood; D C Davies
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

Review 8.  Insulin resistance in Alzheimer's disease.

Authors:  Thomas Diehl; Roger Mullins; Dimitrios Kapogiannis
Journal:  Transl Res       Date:  2016-12-13       Impact factor: 7.012

Review 9.  Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.

Authors:  Lisa Mosconi; Alberto Pupi; Mony J De Leon
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 10.  Adverse stress, hippocampal networks, and Alzheimer's disease.

Authors:  Sarah M Rothman; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2009-11-27       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.